BIOMAT Database Logo BIOMAT Database Logo

An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. 2001

B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Welwyn, Herts, United Kingdom.

The oral pharmacokinetics of cilomilast (Ariflo) were investigated in five separate studies in healthy volunteers. Cilomilast was rapidly absorbed, and pharmacokinetics were dose proportional after single and repeat dosing. The elimination half-life was 7 to 8 hours; accordingly, steady state was reached on the 3rd day of dosing. The degree of accumulation following repeat twice-daily dosing was predictable from the data following a single dose. Although systemic exposure (AUC) was, on average, 21% higher in elderly (65-84 years) compared with young subjects, values for Cmax and t(1/2) were similar, and no difference in tolerability was noted. Single and repeat doses of cilomilast up to and including 15 mg (dosed before or taken between meals) were well tolerated. Dosing with food reduced the rate of absorption without affecting total bioavailability. Hence, tolerability was optimal in the fed state; repeat doses up to and including 30 mg twice daily aftermeals were well tolerated following dose titration.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D003509 Cyclohexanecarboxylic Acids Carboxylic acid derivatives of cyclohexane. Acids, Cyclohexanecarboxylic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
May 2005, Expert review of clinical immunology,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
October 2003, American journal of respiratory and critical care medicine,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.
October 2006, The Annals of pharmacotherapy,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.
June 2001, Pharmacotherapy,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Clarithromycin pharmacokinetics in healthy young and elderly volunteers.
November 1992, Journal of clinical pharmacology,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
The pharmacokinetics of zileuton in healthy young and elderly volunteers.
January 1995, Clinical pharmacokinetics,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
January 2000, The Journal of international medical research,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
May 1999, Journal of clinical pharmacology,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
June 1997, British journal of clinical pharmacology,
B D Zussman, and L J Benincosa, and D M Webber, and D J Clark, and H Cowley, and J Kelly, and R D Murdoch, and J Upward, and P Wyld, and A Port, and H Fuder
ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
June 2011, International immunopharmacology,
Copied contents to your clipboard!